{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:04:03Z","timestamp":1785683043262,"version":"3.56.0"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Genetic alterations that affect the function of p53 tumor suppressor have been extensively investigated in myeloid neoplasms, revealing their significant impact on disease progression, treatment response, and patient outcomes. The identification and characterization of TP53 mutations play pivotal roles in subclassifying myeloid neoplasms and guiding treatment decisions. Starting with the presentation of a typical case, this review highlights the complicated nature of genetic alterations involving TP53 and provides a comprehensive analysis of TP53 mutations and other alterations in myeloid neoplasms. Currently available methods used in clinical laboratories to identify TP53 mutations are discussed, focusing on the importance of establishing a robust testing protocol within clinical laboratories to ensure the delivery of accurate and reliable results. The treatment implications of TP53 mutations in myeloid neoplasms and clinical trial options are reviewed. Ultimately, we hope that this review provides valuable insights into the patterns of TP53 alterations in myeloid neoplasms and offers guidance to establish practical laboratory testing protocols to support the best practices of precision oncology.<\/jats:p>","DOI":"10.1093\/labmed\/lmae048","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T08:41:52Z","timestamp":1720860112000},"page":"686-699","source":"Crossref","is-referenced-by-count":10,"title":["<i>TP53<\/i> mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-075X","authenticated-orcid":false,"given":"Linsheng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, GA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooj","family":"Abro","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, GA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Geisinger Medical Center , Danville, PA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Geisinger Medical Center , Danville, PA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"issue":"22","key":"2024110408210008600_CIT0001","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med."},{"issue":"10","key":"2024110408210008600_CIT0002","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med."},{"issue":"7","key":"2024110408210008600_CIT0003","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"issue":"7","key":"2024110408210008600_CIT0004","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"issue":"11","key":"2024110408210008600_CIT0005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood."},{"key":"2024110408210008600_CIT0006","author":"Wang","year":"2022"},{"key":"2024110408210008600_CIT0007","doi-asserted-by":"crossref","first-page":"593383","DOI":"10.3389\/fonc.2020.593383","article-title":"Heterogeneity of TP53 mutations and p53 protein residual function in cancer: does it matter","volume":"10","author":"Monti","year":"2020","journal-title":"Front Oncol."},{"issue":"8","key":"2024110408210008600_CIT0008","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"issue":"269","key":"2024110408210008600_CIT0009","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"2024110408210008600_CIT0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"12","key":"2024110408210008600_CIT0011","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jamaoncol.2021.4398","article-title":"Analysis of the Li-Fraumeni spectrum based on an international germline TP53 variant data set: an International Agency for Research on Cancer TP53 database analysis","volume":"7","author":"Kratz","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024110408210008600_CIT0012","author":"National Cancer Institute (NCI) of the National Institutes of Health","year":"2024","journal-title":"The TP53 Database. (R20, July 2019)"},{"issue":"14","key":"2024110408210008600_CIT0013","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis","volume":"100","author":"Kato","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"2024110408210008600_CIT0014","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tig.2022.02.010","article-title":"The p53 network: cellular and systemic DNA damage responses in cancer and aging","volume":"38","author":"Vaddavalli","year":"2022","journal-title":"Trends Genet."},{"issue":"11","key":"2024110408210008600_CIT0015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"2024110408210008600_CIT0016","doi-asserted-by":"crossref","first-page":"1904309","DOI":"10.1155\/2023\/1904309","article-title":"Immunological role of TP53 somatic mutation classification in human cancers","volume":"2023","author":"Fang","year":"2023","journal-title":"J Oncol"},{"issue":"3","key":"2024110408210008600_CIT0017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers16030514","article-title":"Molecular genetic profile of myelofibrosis: implications in the diagnosis, prognosis, and treatment advancements","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2024110408210008600_CIT0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases","volume":"8","author":"Ok","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2024110408210008600_CIT0019","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med."},{"issue":"23","key":"2024110408210008600_CIT0020","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"26","key":"2024110408210008600_CIT0021","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med."},{"issue":"12","key":"2024110408210008600_CIT0022","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood."},{"issue":"1","key":"2024110408210008600_CIT0023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of \u226510% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J."},{"issue":"15","key":"2024110408210008600_CIT0024","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood."},{"issue":"10393","key":"2024110408210008600_CIT0025","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet."},{"issue":"20","key":"2024110408210008600_CIT0026","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer."},{"issue":"7540","key":"2024110408210008600_CIT0027","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature."},{"issue":"26","key":"2024110408210008600_CIT0028","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med."},{"key":"2024110408210008600_CIT0029","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol."},{"key":"2024110408210008600_CIT0030","first-page":"144","article-title":"TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease","volume-title":"Nat Cardiovasc Res.","author":"Zekavat","year":"2023"},{"issue":"25","key":"2024110408210008600_CIT0031","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood."},{"issue":"5","key":"2024110408210008600_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid."},{"issue":"5","key":"2024110408210008600_CIT0033","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in the Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"2024110408210008600_CIT0034","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","article-title":"Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia","volume":"16","author":"Bahaj","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2024110408210008600_CIT0035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/cancers12030637","article-title":"Functional classification of TP53 mutations in acute myeloid leukemia","volume":"12","author":"Dutta","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"2024110408210008600_CIT0036","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","article-title":"A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol Cell."},{"key":"2024110408210008600_CIT0037","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2019-130545","article-title":"Evolutionary action (EA) score of TP53 mutations defines prognostic subsets within TP53 mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"134","author":"Kanagal-Shamanna","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2024110408210008600_CIT0038","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical implications of subclonal TP53 mutations in acute myeloid leukemia","volume":"104","author":"Prochazka","year":"2019","journal-title":"Haematologica."},{"issue":"9","key":"2024110408210008600_CIT0039","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1038\/s41375-022-01652-8","article-title":"High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance","volume":"36","author":"Yang","year":"2022","journal-title":"Leukemia."},{"issue":"12","key":"2024110408210008600_CIT0040","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/ijc.33942","article-title":"Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML\/MDS patients","volume":"150","author":"Gerding","year":"2022","journal-title":"Int J Cancer."},{"issue":"6","key":"2024110408210008600_CIT0041","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1309\/AJCPP6LVMQG4LNCK","article-title":"Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia","volume":"143","author":"He","year":"2015","journal-title":"Am J Clin Pathol."},{"issue":"5","key":"2024110408210008600_CIT0042","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ajcp\/aqy002","article-title":"Limited utility of fluorescence in situ hybridization for recurrent abnormalities in acute myeloid leukemia at diagnosis and follow-up","volume":"149","author":"Wheeler","year":"2018","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"2024110408210008600_CIT0043","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12863-020-00956-x","article-title":"A simple method to estimate the in-house limit of detection for genetic mutations with low allele frequencies in whole-exome sequencing analysis by next-generation sequencing","volume":"22","author":"Miura","year":"2021","journal-title":"BMC Genom Data"},{"key":"2024110408210008600_CIT0044","author":"Memorial Sloan Kettering Cancer Center (MSK)","year":"2024","journal-title":"The cBioPortal for Cancer Genomics"},{"key":"2024110408210008600_CIT0045","author":"Memorial Sloan Kettering Cancer Center (MSK)","year":"2024","journal-title":"OncoKB\u2122. Updated"},{"key":"2024110408210008600_CIT0046","author":"The Jackson Laboratory","year":"2018-2024","journal-title":"CKB Boost\u2122"},{"issue":"5","key":"2024110408210008600_CIT0047","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med."},{"issue":"1","key":"2024110408210008600_CIT0048","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn."},{"issue":"3","key":"2024110408210008600_CIT0049","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/humu.24152","article-title":"Specifications of the ACMG\/AMP variant interpretation guidelines for germline TP53 variants","volume":"42","author":"Fortuno","year":"2021","journal-title":"Hum Mutat."},{"issue":"1","key":"2024110408210008600_CIT0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjh.13529","article-title":"TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis","volume":"171","author":"Loghavi","year":"2015","journal-title":"Br J Haematol."},{"issue":"4","key":"2024110408210008600_CIT0051","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/his.14726","article-title":"Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia","volume":"81","author":"Fitzpatrick","year":"2022","journal-title":"Histopathology."},{"issue":"3","key":"2024110408210008600_CIT0052","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/modpathol.2016.206","article-title":"Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis","volume":"30","author":"Fernandez-Pol","year":"2017","journal-title":"Mod Pathol."},{"issue":"8","key":"2024110408210008600_CIT0053","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.3324\/haematol.2016.143214","article-title":"Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"101","author":"McGraw","year":"2016","journal-title":"Haematologica."},{"issue":"8","key":"2024110408210008600_CIT0054","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3324\/haematol.2018.205302","article-title":"TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies","volume":"104","author":"Ruzinova","year":"2019","journal-title":"Haematologica."},{"issue":"1","key":"2024110408210008600_CIT0055","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.acpath.2022.100064","article-title":"Utilizing digital pathology and immunohistochemistry of p53 as an adjunct to molecular testing in myeloid disorders","volume":"10","author":"Rogers","year":"2023","journal-title":"Acad Pathol"},{"key":"2024110408210008600_CIT0056","author":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2024","journal-title":"Acute myeloid leukemia"},{"key":"2024110408210008600_CIT0057","author":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2024","journal-title":"Myelodysplastic syndromes"},{"issue":"9","key":"2024110408210008600_CIT0058","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood."},{"key":"2024110408210008600_CIT0059","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2018-99-117772","article-title":"TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia","volume":"132","author":"Goldberg","year":"2018","journal-title":"Blood."},{"key":"2024110408210008600_CIT0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.leukres.2018.05.011","article-title":"The FOSSIL Study: FLAG or standard 7 + 3 induction therapy in secondary acute myeloid leukemia","volume":"70","author":"Vulaj","year":"2018","journal-title":"Leuk Res."},{"issue":"7","key":"2024110408210008600_CIT0061","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res."},{"issue":"12","key":"2024110408210008600_CIT0062","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"2024110408210008600_CIT0063","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMc1616062","article-title":"Decitabine in TP53-mutated AML","volume":"376","author":"Montalban-Bravo","year":"2017","journal-title":"N Engl J Med."},{"issue":"21","key":"2024110408210008600_CIT0064","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"2024110408210008600_CIT0065","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14455","article-title":"TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes","volume":"176","author":"Chang","year":"2017","journal-title":"Br J Haematol."},{"issue":"14","key":"2024110408210008600_CIT0066","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/bloodadvances.2022009564","article-title":"Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms","volume":"7","author":"Nannya","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"2024110408210008600_CIT0067","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16166","article-title":"Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia","volume":"187","author":"Aldoss","year":"2019","journal-title":"Br J Haematol."},{"issue":"1","key":"2024110408210008600_CIT0068","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"issue":"10","key":"2024110408210008600_CIT0069","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2024110408210008600_CIT0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"2024110408210008600_CIT0071","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2024110408210008600_CIT0072","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2024110408210008600_CIT0073","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol."},{"issue":"4","key":"2024110408210008600_CIT0074","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-023-05462-5","article-title":"TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches","volume":"103","author":"Pereira","year":"2024","journal-title":"Ann Hematol."},{"issue":"1","key":"2024110408210008600_CIT0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-023-01431-7","article-title":"Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2024110408210008600_CIT0076","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br J Haematol."},{"issue":"14","key":"2024110408210008600_CIT0077","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1080\/10428194.2022.2123228","article-title":"Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"63","author":"Shahzad","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"2024110408210008600_CIT0078","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia."},{"issue":"3","key":"2024110408210008600_CIT0079","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3324\/haematol.2023.283886","article-title":"Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation","volume":"109","author":"Pasca","year":"2024","journal-title":"Haematologica."},{"issue":"14","key":"2024110408210008600_CIT0080","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol."},{"key":"2024110408210008600_CIT0081","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2021-147962","article-title":"Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)","volume":"138","author":"Mishra","year":"2021","journal-title":"Blood."},{"issue":"4","key":"2024110408210008600_CIT0082","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"key":"2024110408210008600_CIT0083","author":"Aprea Therapeutics","year":"2020"},{"issue":"23","key":"2024110408210008600_CIT0084","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"El Chaer","year":"2023","journal-title":"Blood."},{"issue":"34","key":"2024110408210008600_CIT0085","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol."},{"key":"2024110408210008600_CIT0086","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.2147\/OTT.S172315","article-title":"MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)","volume":"12","author":"Khurana","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"14","key":"2024110408210008600_CIT0087","first-page":"4147","article-title":"Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial","volume":"6","author":"Konopleva","year":"2022","journal-title":"Blood Adv."},{"issue":"11","key":"2024110408210008600_CIT0088","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood."},{"issue":"13","key":"2024110408210008600_CIT0089","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/fon-2020-0044","article-title":"MIRROS: a randomized, placebo-controlled, phase III trial of cytarabine \u00b1 idasanutlin in relapsed or refractory acute myeloid leukemia","volume":"16","author":"Montesinos","year":"2020","journal-title":"Future Oncol."},{"key":"2024110408210008600_CIT0090","doi-asserted-by":"crossref","first-page":"121361","DOI":"10.1016\/j.lfs.2022.121361","article-title":"Mutant P53 in the formation and progression of the tumor microenvironment: friend or foe","volume":"315","author":"Asl","year":"2023","journal-title":"Life Sci."},{"issue":"20","key":"2024110408210008600_CIT0091","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv."},{"issue":"10","key":"2024110408210008600_CIT0092","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med."},{"issue":"3","key":"2024110408210008600_CIT0093","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"issue":"20","key":"2024110408210008600_CIT0094","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer."},{"key":"2024110408210008600_CIT0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II Study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood."},{"key":"2024110408210008600_CIT0096","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1182\/blood-2022-160337","article-title":"Nature of clinical response and depth of molecular response in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) treated with magrolimab with azacitidine","volume":"140","author":"Johnson","year":"2022","journal-title":"Blood."},{"issue":"1","key":"2024110408210008600_CIT0097","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-023-01411-x","article-title":"Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting","volume":"16","author":"DiNardo","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2024110408210008600_CIT0098","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/6\/686\/60250722\/lmae048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/6\/686\/60250722\/lmae048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:23:07Z","timestamp":1730708587000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/55\/6\/686\/7713136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":98,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,13]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmae048","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,13]]}}}